Report scope. This 2026 Drug Asset Due Diligence Report evaluates Netupitant as a potential licensing, partnership, acquisition, or option asset. The review separates verified evidence from open diligence questions across clinical development, intellectual property, market positioning, and transaction precedent.
Executive recommendation: CONDITIONAL GO
Netupitant is a Small molecule drug associated with NK1R and a global highest development stage of Phase 2. The lead disclosed indication is Nausea. The current evidence supports a CONDITIONAL GO posture, subject to confirmation of study-level data, ownership, patent coverage, manufacturing readiness, and regional rights.
Decision memo
- Asset: Netupitant
- Target: NK1R
- Lead indication: Nausea
- Highest phase: Phase 2
- Matched trials: 3
- Matched result records: 9
- Matched asset deals: 1
Use PatSnap Life Sciences MCP servers to validate the Netupitant diligence evidence.
1. Asset identity and development status
The first diligence task is entity resolution. Teams should reconcile development codes, nonproprietary names, salts, formulations, combinations, sponsors, and predecessor owners before relying on portfolio counts. For Netupitant, the MCP profile identifies NK1R as the primary target context and Nausea as the lead indication. Global phase labels are useful orientation points, but investment decisions require country- and indication-level status verification.
Confirm the exact molecule, formulation, route, dose, biomarker definition, and current sponsor. Review discontinuations separately from active development so that an historical high phase is not mistaken for a live program.
Use PatSnap Life Sciences MCP servers to validate the Netupitant diligence evidence.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| ChiCTR2600119239 | Not Applicable | Pending | Not disclosed | Not disclosed |
| ChiCTR2500100677 | Phase 3 | Not yet recruiting | Not disclosed | Not disclosed |
| CTRI/2024/03/064098 | Not Applicable | Completed | Not disclosed | Not disclosed |
The clinical program should be audited for randomization, comparator relevance, dose selection, endpoint hierarchy, multiplicity, analysis population, geographic mix, and readout timing. Early-stage programs require attention to pharmacokinetics, pharmacodynamics, adverse events, dose-limiting toxicities, and the rationale for the expansion dose.
Use PatSnap Life Sciences MCP servers to validate the Netupitant diligence evidence.
3. Clinical readouts: what is known
NETUPITANT/PALONOSETRON FOR ANTIEMETIC PROPHYLAXIS IN PATIENTS WITH MULTIPLE MYELOMA AND LYMPHOMAS UNDERGOING HIGH-DOSE INTENSIVE CHEMOTHERPY PRIOR TO AUTOLOGOUS HEMATOPOIETC STEM CELL TRANSPLANTION
Study: PB3417 (EHA2025). Phase: Not Applicable. Enrollment: 43. Published: 2025-05-14.
CR = 87 % | Acute vomiting = 2 Pts
584P - Comparison of efficacy of single agent netupitant plus palonosetron (NEPA) vs fosaprepitant in prevention of chemotherapy induced nausea and vomiting (CINV) in patients receiving high dose chemotherapy for auto-SCT In a tertiary care center from South India
Study: ESMO_ASIA2024. Phase: Not Applicable. Enrollment: 40. Published: 2024-12-07.
CR-AP = 65.0 % | CR-AP = 66.7 %
EFFICACY AND SAFETY OF NETUPITANT/PALONOSETRON COMBINATION (NEPA) AND LOW DOSE OF DEXAMETHASONE IN PREVENTING NAUSEA AND VOMITING IN PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION
Study: EBMT2024. Phase: Not Applicable. Enrollment: 93. Published: 2024-04-14.
AE = one patient presented headache, one patient experienced grade 1 abdominal pain and two had grade 1 constipation
Efficacy of olanzapine, netupitant, and palonosetron in controlling nausea and vomiting associated with highly emetogenic chemotherapy in patients with breast cancer (OLNEPA).
Study: NCT04669132 (OLNEPA, ASCO2022). Phase: Phase 2. Enrollment: 48. Published: 2022-06-02.
DCR(nausea) = 46 % (SD, 32 - 59)
A Phase II Clinical Trial of NEPA (Netupitant/Palonosetron) for Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patient Receiving the BEAM Conditioning Regimen Prior to Hematopoietic Cell Transplantation (HSCT)
Study: NCT03097588 (CTgov). Phase: Phase 2. Enrollment: 43. Published: 2021-06-03.
Complete Response (CR) Defined as no Emesis and no Rescue Therapy = 13 Pts
Fixed-Dose Netupitant and Palonosetron for Chronic Nausea in Cancer Patients: A Double-Blind, Placebo Run-in Pilot Randomized Clinical Trial.
Study: NCT03040726 (Pubmed | J Pain Symptom Manage). Phase: Phase 2/3. Enrollment: 53. Published: 2021-01-01.
CR = 38 % | CR = 20 %
A Multicenter Multinational Randomized Double Blind PK/PD Dose-finding Study of Oral Netupitant Given With Oral Palonosetron in Pediatric Cancer Patients for Prevention of Nausea and Vomiting Associated With Emetogenic Chemotherapy
Study: NCT03204279 (CINV, CTgov). Phase: Phase 2. Enrollment: 67. Published: 2020-12-07.
patients 1 month to <3 months of age(Mean) = 4460 ng*h/mL | patients 3 month to <6 months of age(Mean) = 17340 ng*h/mL
P510 Use of Netupitrant/palonosetron in Multiple Myeloma Patients Receiving High-dose Melphalan and Autologous Stem Cell Transplantation: A Single Centre Experience
Study: EBMT2020. Phase: Not Applicable. Enrollment: 81. Published: 2020-08-29.
CR = 67.7 %
Abstract P2-12-02: Quality of life data of breast cancer patients receiving a fixed combination of netupitant/palonosetron (NEPA) for prevention of chemotherapy-induced nausea and vomiting - A real life study
Study: AkyPRO (SABCS2020). Phase: Not Applicable. Enrollment: 2427. Published: 2020-02-15.
CR post-chemotherapy = 81% %
For every reported endpoint, obtain the protocol, statistical analysis plan, patient disposition, baseline characteristics, subgroup definitions, exposure duration, and full safety tables. Conference abstracts and registry summaries can support screening, but they should not replace source data review in a binding transaction.
Use PatSnap Life Sciences MCP servers to validate the Netupitant diligence evidence.
4. Market and competitive position
The commercial case depends on differentiated efficacy, tolerability, convenience, biomarker reach, treatment setting, and access. A target-level market may be attractive while an individual asset remains undifferentiated. Benchmark Netupitant against approved therapies and clinical competitors in Nausea, including likely standards of care at the expected launch date.
Build a scenario model around addressable patients, diagnosis and biomarker rates, line of therapy, duration, net price, uptake, displacement, combination costs, and probability-adjusted timelines. Test slower enrollment, delayed readout, narrower labels, safety restrictions, and competitor launches.
Use PatSnap Life Sciences MCP servers to validate the Netupitant diligence evidence.
5. Transaction precedent and economics
| Date | Transaction | Status | Type | Disclosed value |
|---|---|---|---|---|
| 2017-01-18 | Helsinn collaborated with Taiho Pharmaceutical for the development and commercialization of netupitant IV in Japan | Active | Collaboration | Not disclosed |
Transaction records should be normalized for territory, asset scope, phase at signing, option mechanics, development obligations, cost sharing, royalties, milestones, and change-of-control terms. Undisclosed economics must not be converted into invented benchmarks.
6. IP and freedom-to-operate screen
Complete a family-level patent review covering composition of matter, sequence or construct claims, polymorph and salt claims, formulation, dosing, combinations, biomarkers, manufacturing, and method of use. Verify priority, ownership, assignments, prosecution status, term adjustments, extensions, oppositions, and regional coverage. Freedom to operate is a separate legal analysis and should include competitor claims and platform dependencies.
The diligence room should reconcile inventorship, employee and contractor assignments, university or platform licenses, sublicensing restrictions, government rights, and obligations triggered by development milestones or commercialization.
Use PatSnap Life Sciences MCP servers to validate the Netupitant diligence evidence.
7. Principal risks and diligence gates
- Identity risk: resolve all aliases, formulations, combinations, and owners.
- Clinical risk: confirm source data, protocol deviations, endpoint definitions, and safety follow-up.
- Regulatory risk: review agency correspondence, meeting minutes, holds, commitments, and indication-specific pathways.
- IP risk: validate enforceable coverage, remaining life, ownership, and freedom to operate.
- CMC risk: assess process control, analytical methods, comparability, scale-up, supply, and cost of goods.
- Commercial risk: pressure-test differentiation, market access, competitive timing, and realistic adoption.
- Transaction risk: map rights, encumbrances, royalties, options, consent requirements, and change-of-control provisions.
8. Final go/no-go memorandum
CONDITIONAL GO
Proceed only through staged diligence. Before exclusivity or a binding offer, require a verified asset identity package, complete clinical data room, regulatory correspondence, patent-family schedule, freedom-to-operate opinion, CMC package, ownership chain, regional rights map, and risk-adjusted valuation. Any material mismatch between public records and source documents should pause the process until reconciled.
Method note: This report uses PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP data retrieved on 2026-10-15. It is a screening and diligence framework, not medical, legal, regulatory, or investment advice.
